This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to discover a safe and effective long-acting antiviral therapy for hepatitis B (HBV) that can provide sustained viral suppression. The $762,072 grant will fund a 5-year translational research project to leverage expertise and collaborative capacity to transform current short-acting oral antiviral drugs into a long-acting...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $3,056,673 to The Johns Hopkins University to conduct research on improving hepatitis B vaccine responses in people living with HIV. The key objectives are to: Define the innate immune signatures induced by the HEPLISAV-B vaccine (containing the CPG 1018 adjuvant) compared to the standard ENGERIX-B vaccine, and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA Program 93.855 - Allergy and Infectious Diseases Research provides $883,119 to the Scripps Research Institute to develop a novel mRNA-based vaccine and immunotherapy against hepatitis B virus (HBV). The key products and services to be delivered under this 1-year award include: Investigating viral and cellular factors that hinder effective antigen expression for HBV vaccines, and...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to uncover the mechanism underlying hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) transcriptional silencing in individuals with HBV mono-infection and HBV/HIV co-infection. The $2,279,005 award, effective from July 2024 through May 2029, will enable researchers at The Johns Hopkins...
This is a Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), totaling $2,225,199 and effective from July 1, 2024 to May 31, 2029. The primary objective is to identify the key immune correlates and mechanisms underlying functional cure of hepatitis B virus (HBV) infection. The research will define the roles of HBV-specific CD4 T cells and B cells in viral control and pathogenesis,...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is providing $510,306 to Emory University to support research into virus-host interactions that could lead to a cure for chronic hepatitis B virus (HBV) infections. The project aims to advance understanding of the mechanisms by which HBV genotypes and mutations affect disease progression and response to interferon-alpha...
This $814,790 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to uncover the immune mechanisms underlying the clearance of hepatitis B virus (HBV) surface antigen (HBsAg) in chronic HBV patients. The research is being conducted by a team of investigators at the University of California, San Francisco (UCSF), with the goal of advancing the understanding of HBsAg...
The Department of the Army Medical Command awarded a $5.5 million Project Grant to Carogen Corporation to support the Combination of HBV Immunotherapy with shRNA-Mediated PD-1/PDL Checkpoint Inhibition for Treatment of Chronic HBV from September 15, 2022 through September 14, 2025. This funding supports research under the Military Medical Research and Development program (CFDA 12.420), which aims to transform military and public health care through innovative biomedical research and develop...
This federal Project Grant award of $234,735.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the immune mechanisms that influence hepatitis B virus (HBV) clearance. The key objectives are to: 1) Examine the role of co-stimulatory signaling pathways in the age-dependent capacity of hepatic conventional dendritic cells to activate CD4+ T cells, and...
This $2,357,206 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop an immunocompetent mouse model susceptible to hepatitis B virus (HBV) infection. The goal is to identify host and viral factors that can overcome the species barrier and enable HBV infection and persistence in murine hepatocytes. Key objectives include determining if genetic diversity...